Your browser doesn't support javascript.
loading
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis.
Viscardi, Giuseppe; Tralongo, Antonino C; Massari, Francesco; Lambertini, Matteo; Mollica, Veronica; Rizzo, Alessandro; Comito, Francesca; Di Liello, Raimondo; Alfieri, Salvatore; Imbimbo, Martina; Della Corte, Carminia M; Morgillo, Floriana; Simeon, Vittorio; Lo Russo, Giuseppe; Proto, Claudia; Prelaj, Arsela; De Toma, Alessandro; Galli, Giulia; Signorelli, Diego; Ciardiello, Fortunato; Remon, Jordi; Chaput, Nathalie; Besse, Benjamin; de Braud, Filippo; Garassino, Marina C; Torri, Valter; Cinquini, Michela; Ferrara, Roberto.
Afiliação
  • Viscardi G; Medical Oncology, Department of Precision Medicine, Università Degli Studi Della Campania "Luigi Vanvitelli", Naples, Italy; Department of Pneumology and Oncology, AORN Ospedali Dei Colli, Naples, Italy. Electronic address: https://twitter.com/@giusvisc.
  • Tralongo AC; Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy; Medical Oncology Unit, Umberto I Hospital, Azienda Sanitaria Provinciale (ASP) Siracusa, Siracusa, Italy.
  • Massari F; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Lambertini M; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy; Department of Medical Oncology, UO Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Mollica V; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Rizzo A; SSD Oncologia Medica per La Presa in Carico Globale Del Paziente Oncologico "Don Tonino Bello", IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
  • Comito F; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Di Liello R; Clinical Trials Unit, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Naples, Italy.
  • Alfieri S; Head and Neck Medical Oncology 3 Department, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
  • Imbimbo M; Department of Oncology, Immuno-oncology Service, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
  • Della Corte CM; Medical Oncology, Department of Precision Medicine, Università Degli Studi Della Campania "Luigi Vanvitelli", Naples, Italy.
  • Morgillo F; Medical Oncology, Department of Precision Medicine, Università Degli Studi Della Campania "Luigi Vanvitelli", Naples, Italy.
  • Simeon V; Medical Statistics Unit, Department of Mental Health and Public Medicine, Università Degli Studi Della Campania "Luigi Vanvitelli", Naples, Italy.
  • Lo Russo G; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
  • Proto C; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
  • Prelaj A; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
  • De Toma A; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
  • Galli G; Medical Oncology Unit, Policlinico San Matteo Fondazione IRCCS, Pavia, Italy.
  • Signorelli D; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • Ciardiello F; Medical Oncology, Department of Precision Medicine, Università Degli Studi Della Campania "Luigi Vanvitelli", Naples, Italy.
  • Remon J; Department of Medical Oncology, Centro Integral Oncológico Clara Campal (HM-CIOCC), Hospital Delfos, Barcelona, Spain.
  • Chaput N; Laboratory of Immunomonitoring in Oncology, Gustave Roussy, Villejuif, France; Faculty of Pharmacy, University Paris-Saclay, Chatenay-Malabry, France.
  • Besse B; Cancer Medicine Department, Gustave Roussy, Villejuif, France; Faculty of Medicine, University Paris-Saclay, Le Kremlin Bicêtre, France.
  • de Braud F; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
  • Garassino MC; Department of Medicine, University of Chicago; University of Chicago Comprehensive Cancer Center, Chicago, USA.
  • Torri V; Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
  • Cinquini M; Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
  • Ferrara R; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy. Electronic address: roberto.ferrara@istitutotumori.mi.it.
Eur J Cancer ; 177: 175-185, 2022 12.
Article em En | MEDLINE | ID: mdl-36368251
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Checkpoint Imunológico / Neoplasias Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Checkpoint Imunológico / Neoplasias Idioma: En Ano de publicação: 2022 Tipo de documento: Article